+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

COPD and Asthma Therapeutics Market Size, Share & Trends Analysis Report by Drug Class (Anti-Inflammatory, Bronchodilators), Device/Product (Inhalers), Technology/Software, Indication, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 120 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098064
REQUEST CUSTOMIZATION
Description Jump to:
The COPD and Asthma Therapeutics Market was valued at USD 92.30 billion in 2024, and is projected to reach USD 155.25 billion by 2030, rising at a CAGR of 9.18%. The increasing prevalence of chronic respiratory conditions, exacerbated by rising pollution levels, tobacco consumption, and aging populations, is significantly boosting demand for bronchodilators, corticosteroids, and combination therapies.

For instance, according to the Global Initiative for Asthma (GINA), asthma affected over 262 million people globally in 2022, while the WHO reported that COPD was the third leading cause of death worldwide. In addition, a growing aging population coupled with increasing automotive and industrial exhaust gases remains the key driver for the global COPD and asthma therapeutics industry. Degrading air quality near industrial areas has led to an increased incidence of asthma. According to the European Environment Agency, air pollutant levels in 2021 significantly exceeded the levels specified by the World Health Organization's (WHO) air quality guidelines. Achieving these recommended levels could have prevented a significant number of deaths across EU Member States (EU-27), including 253,000 deaths linked to exposure to fine particulate matter (PM2.5) and 52,000 deaths caused by nitrogen dioxide (NO2) exposure. In addition, reducing short-term exposure to ozone (O3) could have reduced 22,000 attributable deaths.

The COPD and asthma therapeutics market is also propelled by technological advancements in drug delivery devices, such as smart inhalers with Bluetooth connectivity and AI-based respiratory monitoring platforms, which enhance treatment adherence and enable remote patient management. Companies like Propeller Health and Teva have introduced FDA-approved smart inhalers that track medication usage and transmit data to clinicians in real time.

Moreover, the growing penetration of mobile health apps and telepulmonology solutions is improving access to care, especially in underserved areas. The expansion of online pharmacies and direct-to-consumer digital platforms is also streamlining therapy access, supporting the shift towards home-based disease management. Collectively, these advancements across therapeutic classes, delivery devices, and digital tools are expected to drive sustained growth in the COPD and asthma market through 2030.

Increasing healthcare expenditure, improved access to care in developing regions, and supportive government initiatives aimed at managing chronic respiratory conditions are further enhancing market potential. The rise of universal healthcare programs in countries such as India and China is expanding access to essential inhalers and diagnostics. For instance, China's Healthy China 2030 initiative focuses on four strategic pillars: equitable access and outcomes in health and healthcare, healthcare systems transformation, technology and innovation, and environmental and climate sustainability. Equity is the foundational goal, guiding efforts to reduce barriers in healthcare systems and improve health outcomes across the country.

The COVID-19 pandemic positively impacted the COPD and asthma therapeutics industry. Initially, disruptions in healthcare access, reduced pulmonary function testing, and delayed diagnoses led to a decline in treatment rates and prescription volumes. However, as the pandemic progressed, heightened awareness of respiratory health and the increased risk of severe COVID-19 outcomes in patients with chronic lung diseases drove greater adherence to maintenance therapies. The shift toward home-based care, telemedicine, and digital health tools, such as smart inhalers and remote monitoring, supported continued treatment and patient engagement. While the market faced short-term setbacks, the pandemic ultimately reinforced the importance of proactive respiratory care, leading to long-term growth opportunities.

Global COPD And Asthma Therapeutics Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global COPD and asthma therapeutics market report based on drug class, device/product, technology/software, indication, distribution channel, and region:

Drug Class Outlook (Revenue, USD Million, 2018-2030)

  • Bronchodilators
  • Corticosteroids
  • Leukotriene Modifiers
  • Anti-IgE and Anti-IL Monoclonal Antibodies
  • Combination Therapy
  • Others

Device/Product Outlook (Revenue, USD Million, 2018-2030)

  • Inhalers
  • Dry Powder Inhalers (DPI)
  • Metered Dose Inhalers (MDI)
  • Soft Mist Inhalers (SMI)
  • Nebulizers
  • Jet
  • Mesh
  • Ultrasonic
  • Oxygen Therapy Devices

Technology/Software Outlook (Revenue, USD Million, 2018-2030)

  • Smart Inhalers with Bluetooth Connectivity
  • AI-based Respiratory Monitoring Platforms
  • Mobile Apps for Symptom Tracking
  • Digital Adherence and Reminder Systems
  • Telepulmonology Solutions

Indication Outlook (Revenue, USD Million, 2018-2030)

  • Asthma
  • COPD

Distribution Channel Outlook (Revenue, USD Million, 2018-2030)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Drug Stores

Regional Outlook (Revenue, USD Million, 2018-2030)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Drug Class
1.2.2. Device/Product
1.2.3. Technology/Software
1.2.4. Indication
1.2.5. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Emergence of novel biologics
3.2.1.2. Growing adoption of AI technologies in diagnostics, remote monitoring, and treatment optimization.
3.2.1.3. Advancements in smart inhalers and digital health tools enhancing patient adherence and outcomes.
3.2.1.4. Strong pipeline of innovative drugs and fixed-dose combination therapies.
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory hurdles and lengthy approval timelines for novel therapeutics.
3.2.2.2. High cost of biologics and advanced therapies
3.2.3. Industry Opportunity Analysis
3.2.4. Industry Challenge Analysis
3.2.5. Case Studies
3.3. Business Environment Analysis
3.3.1. Porter’s Five Forces Analysis
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrants
3.3.1.5. Competitive rivalry
3.3.2. PESTLE Analysis
3.4. COVID-19 Impact Analysis
Chapter 4. COPD and Asthma Therapeutics Market: Drug Class Estimates & Trend Analysis
4.1. Drug Class Segment Dashboard
4.2. Drug Class Market Share Movement Analysis, 2024 & 2030
4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2018 to 2030 (USD Million)
4.3.1. Bronchodilators
4.3.1.1. Bronchodilators market, 2018-2030 (USD Million)
4.3.2. Corticosteroids
4.3.2.1. Corticosteroids market, 2018-2030 (USD Million)
4.3.3. Leukotriene Modifiers
4.3.3.1. Leukotriene Modifiers market, 2018-2030 (USD Million)
4.3.4. Anti-IgE and Anti-IL Monoclonal Antibodies
4.3.4.1. Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018-2030 (USD Million)
4.3.5. Combination Therapy
4.3.5.1. Combination Therapy market, 2018-2030 (USD Million)
4.3.6. Others
4.3.6.1. Others market, 2018-2030 (USD Million)
Chapter 5. COPD and Asthma Therapeutics Market: Device/Product Estimates & Trend Analysis
5.1. Device/Product Dashboard
5.2. Device/Product Market Share Movement Analysis, 2024 & 2030
5.3. Market Size & Forecasts and Trend Analysis, by Device/Product, 2018 to 2030 (USD Million)
5.4. Inhalers
5.4.1. Inhalers market, 2018-2030 (USD Million)
5.4.1.1. Dry Powder Inhalers
5.4.1.1.1.Dry Powder Inhalers market, 2018-2030 (USD Million)
5.4.1.2. Metered Dose Inhalers
5.4.1.2.1.Metered Dose Inhalers market, 2018-2030 (USD Million)
5.4.1.3. Soft Mist Inhalers
5.4.1.3.1.Soft Mist Inhalers market, 2018-2030 (USD Million)
5.5. Nebulizers
5.5.1. Nebulizers market, 2018-2030 (USD Million)
5.5.1.1. Jet nebulizers
5.5.1.1.1. Jet nebulizers market, 2018-2030 (USD Million)
5.5.1.2. Mesh nebulizers
5.5.1.2.1. Mesh nebulizers market, 2018-2030 (USD Million)
5.5.1.3. Ultrasonic
5.5.1.3.1. Ultrasonic Inhalers market, 2018-2030 (USD Million)
5.6. Oxygen Therapy Devices
5.6.1. Oxygen Therapy Devices market, 2018-2030 (USD Million)
Chapter 6. COPD and Asthma Therapeutics Market: Technology/Software Estimates & Trend Analysis
6.1. Technology/Software Segment Dashboard
6.2. Technology/Software Market Share Movement Analysis, 2024 & 2030
6.3. Market Size & Forecasts and Trend Analysis, by Technology/Software, 2018 to 2030 (USD Million)
6.4. Smart Inhalers with Bluetooth Connectivity
6.4.1. Smart Inhalers with Bluetooth Connectivity market, 2018-2030 (USD Million)
6.5. AI-based Respiratory Monitoring Platforms
6.5.1. AI-based Respiratory Monitoring Platforms market, 2018-2030 (USD Million)
6.6. Mobile Apps for Symptom Tracking
6.6.1. Mobile Apps for Symptom Tracking market, 2018-2030 (USD Million)
6.7. Digital Adherence and Reminder Systems
6.7.1. Digital Adherence and Reminder Systems market, 2018-2030 (USD Million)
6.8. Telepulmonology Solutions
6.8.1. Telepulmonology Solutions market, 2018-2030 (USD Million)
Chapter 7. COPD and Asthma Therapeutics Market: Indication Estimates & Trend Analysis
7.1. Indication Segment Dashboard
7.2. Indication Market Share Movement Analysis, 2024 & 2030
7.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
7.4. Asthma
7.4.1. Asthma market, 2018-2030 (USD Million)
7.5. COPD
7.5.1. COPD market, 2018-2030 (USD Million)
Chapter 8. COPD and Asthma Therapeutics Market: Distribution Channel Estimates & Trend Analysis
8.1. Distribution Channel Segment Dashboard
8.2. Distribution Channel Market Share Movement Analysis, 2024 & 2030
8.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
8.4. Hospital Pharmacies
8.4.1. Hospital Pharmacies market, 2018-2030 (USD Million)
8.5. Retail Pharmacies
8.5.1. Retail Pharmacies market, 2018-2030 (USD Million)
8.6. Online Pharmacies
8.6.1. Drug Stores market, 2018-2030 (USD Million)
Chapter 9. COPD and Asthma Therapeutics Market: Regional Estimates & Trend Analysis
9.1. Regional Market Dashboard
9.2. Regional Market: Key Takeaways
9.3. North America
9.3.1. North America COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.3.2. U.S.
9.3.2.1. Key country dynamic
9.3.2.2. Regulatory framework
9.3.2.3. Competitive insights
9.3.2.4. U.S. COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.3.3. Canada
9.3.3.1. Key country dynamic
9.3.3.2. Regulatory framework
9.3.3.3. Competitive insights
9.3.3.4. Canada COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.3.4. Mexico
9.3.4.1. Key country dynamic
9.3.4.2. Regulatory framework
9.3.4.3. Competitive insights
9.3.4.4. Mexico COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4. Europe
9.4.1. Europe COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.2. Germany
9.4.2.1. Key country dynamic
9.4.2.2. Regulatory framework
9.4.2.3. Competitive insights
9.4.2.4. Germany COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.3. UK
9.4.3.1. Key country dynamic
9.4.3.2. Regulatory framework
9.4.3.3. Competitive insights
9.4.3.4. UK COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.4. France
9.4.4.1. Key country dynamic
9.4.4.2. Regulatory framework
9.4.4.3. Competitive insights
9.4.4.4. France COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.5. Italy
9.4.5.1. Key country dynamic
9.4.5.2. Regulatory framework
9.4.5.3. Competitive insights
9.4.5.4. Italy COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.6. Spain
9.4.6.1. Key country dynamic
9.4.6.2. Regulatory framework
9.4.6.3. Competitive insights
9.4.6.4. Spain COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.7. Denmark
9.4.7.1. Key country dynamic
9.4.7.2. Regulatory framework
9.4.7.3. Competitive insights
9.4.7.4. Denmark COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.8. Sweden
9.4.8.1. Key country dynamic
9.4.8.2. Regulatory framework
9.4.8.3. Competitive insights
9.4.8.4. Sweden COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.4.9. Norway
9.4.9.1. Key country dynamic
9.4.9.2. Regulatory framework
9.4.9.3. Competitive insights
9.4.9.4. Norway COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5. Asia Pacific
9.5.1. Asia Pacific COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5.2. Japan
9.5.2.1. Key country dynamic
9.5.2.2. Regulatory framework
9.5.2.3. Competitive insights
9.5.2.4. Japan COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5.3. China
9.5.3.1. Key country dynamic
9.5.3.2. Regulatory framework
9.5.3.3. Competitive insights
9.5.3.4. China COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5.4. India
9.5.4.1. Key country dynamic
9.5.4.2. Regulatory framework
9.5.4.3. Competitive insights
9.5.4.4. India COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5.5. South Korea
9.5.5.1. Key country dynamic
9.5.5.2. Regulatory framework
9.5.5.3. Competitive insights
9.5.5.4. South Korea COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5.6. Australia
9.5.6.1. Key country dynamic
9.5.6.2. Regulatory framework
9.5.6.3. Competitive insights
9.5.6.4. Australia COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.5.7. Thailand
9.5.7.1. Key country dynamic
9.5.7.2. Regulatory framework
9.5.7.3. Competitive insights
9.5.7.4. Thailand COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.6. Latin America
9.6.1. Latin America COPD and Asthma Therapeutics Market Estimates and Forecasts, 2018-2030 (USD Million)
9.6.2. Brazil
9.6.2.1. Key country dynamic
9.6.2.2. Regulatory framework
9.6.2.3. Competitive insights
9.6.2.4. Brazil COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.6.3. Argentina
9.6.3.1. Key country dynamic
9.6.3.2. Regulatory framework
9.6.3.3. Competitive insights
9.6.3.4. Argentina COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.7. MEA
9.7.1. MEA COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.7.2. South Africa
9.7.2.1. Key country dynamic
9.7.2.2. Regulatory framework
9.7.2.3. Competitive insights
9.7.2.4. South Africa COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.7.3. Saudi Arabia
9.7.3.1. Key country dynamic
9.7.3.2. Regulatory framework
9.7.3.3. Competitive insights
9.7.3.4. Saudi Arabia COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.7.4. UAE
9.7.4.1. Key country dynamic
9.7.4.2. Regulatory framework
9.7.4.3. Competitive insights
9.7.4.4. UAE COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
9.7.5. Kuwait
9.7.5.1. Key country dynamic
9.7.5.2. Regulatory framework
9.7.5.3. Competitive insights
9.7.5.4. Kuwait COPD and asthma therapeutics market estimates and forecasts, 2018-2030 (USD Million)
Chapter 10. Competitive Landscape
10.1. Participant Overview
10.2. Company Market Position Analysis
10.3. Company Categorization
10.4. Strategy Mapping
10.5. Company Profiles/Listing
10.5.1. Teva Pharmaceutical Industries Ltd.
10.5.1.1. Overview
10.5.1.2. Financial performance
10.5.1.3. Product benchmarking
10.5.1.4. Strategic initiatives
10.5.2. GSK plc
10.5.2.1. Overview
10.5.2.2. Financial performance
10.5.2.3. Product benchmarking
10.5.2.4. Strategic initiatives
10.5.3. Merck & Co., Inc.
10.5.3.1. Overview
10.5.3.2. Financial performance
10.5.3.3. Product benchmarking
10.5.3.4. Strategic initiatives
10.5.4. F. Hoffmann-La Roche Ltd
10.5.4.1. Overview
10.5.4.2. Financial performance
10.5.4.3. Product benchmarking
10.5.4.4. Strategic initiatives
10.5.5. AstraZeneca
10.5.5.1. Overview
10.5.5.2. Financial performance
10.5.5.3. Product benchmarking
10.5.5.4. Strategic initiatives
10.5.6. Boehringer Ingelheim International GmbH
10.5.6.1. Overview
10.5.6.2. Financial performance
10.5.6.3. Product benchmarking
10.5.6.4. Strategic initiatives
10.5.7. Sanofi
10.5.7.1. Overview
10.5.7.2. Financial performance
10.5.7.3. Product benchmarking
10.5.7.4. Strategic initiatives
10.5.8. Koninklijke Philips N.V.
10.5.8.1. Overview
10.5.8.2. Financial performance
10.5.8.3. Product benchmarking
10.5.8.4. Strategic initiatives
10.5.9. BD
10.5.9.1. Overview
10.5.9.2. Financial performance
10.5.9.3. Product benchmarking
10.5.10. Covis Pharma
10.5.10.1. Overview
10.5.10.2. Financial performance
10.5.10.3. Product benchmarking
10.5.11. Findair Sp. z o. o.
10.5.11.1. Overview
10.5.11.2. Financial performance
10.5.11.3. Product benchmarking
10.5.12. Novartis AG
10.5.12.1. Overview
10.5.12.2. Financial performance
10.5.12.3. Product benchmarking
10.5.13. F. Hoffmann-La Roche Ltd
10.5.13.1. Overview
10.5.13.2. Financial performance
10.5.13.3. Product benchmarking
10.5.14. Cipla Ltd.
10.5.14.1. Overview
10.5.14.2. Financial performance
10.5.14.3. Product benchmarking
10.5.15. Chiesi Air
10.5.15.1. Overview
10.5.15.2. Financial performance
10.5.15.3. Product benchmarking
List of Tables
Table 1. List of secondary sources
Table 2. List of abbreviations
Table 3. North America COPD and asthma therapeutics market, by country, 2018-2030 (USD Million)
Table 4. North America COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 5. North America COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 6. North America COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 7. North America COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 8. North America COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 9. U.S. COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 10. U.S. COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 11. U.S. COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 12. U.S. COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 13. U.S. COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 14. Canada COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 15. Canada COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 16. Canada COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 17. Canada COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 18. Canada COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 19. Mexico COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 20. Mexico COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 21. Mexico COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 22. Mexico COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 23. Mexico COPD and asthma therapeutics market, by distribution channel scope, 2018-
Table 24. Europe COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 25. Europe COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 26. Europe COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 27. Europe COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 28. Europe COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 29. UK COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 30. UK COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 31. UK COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 32. UK COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 33. UK COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 34. Germany COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 35. Germany COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 36. Germany COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 37. Germany COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 38. Germany COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 39. France COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 40. France COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 41. France COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 42. France COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 43. France COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 44. Italy COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 45. Italy COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 46. Italy COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 47. Italy COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 48. Italy COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 49. Spain COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 50. Spain COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 51. Spain COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 52. Spain COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 53. Spain COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 54. Norway COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 55. Norway COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 56. Norway COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 57. Norway COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 58. Norway COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 59. Sweden COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 60. Sweden COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 61. Sweden COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 62. Sweden COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 63. Sweden COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 64. Denmark COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 65. Denmark COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 66. Denmark COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 67. Denmark COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 68. Denmark COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 69. Asia Pacific COPD and asthma therapeutics market, by country, 2018-2030 (USD Million)
Table 70. Asia Pacific COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 71. Asia Pacific COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 72. Asia Pacific COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 73. Asia Pacific COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 74. Asia Pacific COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 75. Japan COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 76. Japan COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 77. Japan COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 78. Japan COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 79. Japan COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 80. China COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 81. China COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 82. China COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 83. China COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 84. China COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 85. India COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 86. India COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 87. India COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 88. India COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 89. India COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 90. Australia COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 91. Australia COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 92. Australia COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 93. Australia COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 94. Australia COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 95. South Korea COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 96. South Korea COPD and asthma therapeutics market, by application, 2018-2030 (USD Million)
Table 97. South Korea COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 98. South Korea COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 99. South Korea COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 100. Thailand COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 101. Thailand COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 102. Thailand COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 103. Thailand COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 104. Thailand COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 105. Latin America COPD and asthma therapeutics market, by country, 2018-2030 (USD Million)
Table 106. Latin America COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 107. Latin America COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 108. Latin America COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 109. Latin America COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 110. Latin America COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 111. Brazil COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 112. Brazil COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 113. Brazil COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 114. Brazil COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 115. Brazil COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 116. Argentina COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 117. Argentina COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 118. Argentina COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 119. Argentina COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 120. Argentina COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 121. Middle East & Africa COPD and asthma therapeutics market, by country, 2018-2030 (USD Million)
Table 122. Middle East & Africa COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 123. Middle East & Africa COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 124. Middle East & Africa COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 125. Middle East & Africa COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 126. Middle East & Africa COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 127. South Africa COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 128. South Africa COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 129. South Africa COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 130. South Africa COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 131. South Africa COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 132. Saudi Arabia COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 133. Saudi Arabia COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 134. Saudi Arabia COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 135. Saudi Arabia COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 136. Saudi Arabia COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 137. UAE COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 138. UAE COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 139. UAE COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 140. UAE COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 141. UAE COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
Table 142. Kuwait COPD and asthma therapeutics market, drug class, 2018-2030 (USD Million)
Table 143. Kuwait COPD and asthma therapeutics market, by device/product, 2018-2030 (USD Million)
Table 144. Kuwait COPD and asthma therapeutics market, by technology/software, 2018-2030 (USD Million)
Table 145. Kuwait COPD and asthma therapeutics market, by indication scope, 2018-2030 (USD Million)
Table 146. Kuwait COPD and asthma therapeutics market, by distribution channel scope, 2018-2030 (USD Million)
List of Figures
Figure 1 COPD and asthma therapeutics market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market formulation & validation
Figure 6 Market research approaches
Figure 7 Value-chain-based sizing & forecasting
Figure 8 QFD modelling for market share assessment
Figure 9 Commodity flow analysis
Figure 10 Market snapshot
Figure 11 Market segmentation (USD Million)
Figure 12 Competitive landscape
Figure 13 Parent market outlook (In USD Billion)
Figure 14 Related/ancillary market outlook (In USD Billion)
Figure 15 COPD and asthma therapeutics market dynamics
Figure 16 COPD and asthma therapeutics market: Porter’s five forces analysis
Figure 17 COPD and asthma therapeutics market: PESTLE analysis
Figure 18 COPD and asthma therapeutics market: Drug class segment dashboard
Figure 19 COPD and asthma therapeutics market: Drug class market share analysis, 2024 & 2030
Figure 20 Bronchodilators market, 2018-2030 (USD Million)
Figure 21 Corticosteroids market, 2018-2030 (USD Million)
Figure 22 Leukotriene Modifiers market, 2018-2030 (USD Million)
Figure 23 Anti-IgE and Anti-IL Monoclonal Antibodies market, 2018-2030 (USD Million)
Figure 24 Combination Therapy market, 2018-2030 (USD Million)
Figure 25 Others market, 2018-2030 (USD Million)
Figure 26 COPD and asthma therapeutics market: Device/Product segment dashboard
Figure 27 COPD and asthma therapeutics market: Device/Product market share analysis, 2024 & 2030
Figure 28 Inhalers market, 2018-2030 (USD Million)
Figure 29 Nebulizers market, 2018-2030 (USD Million)
Figure 30 Oxygen Therapy Devices market, 2018-2030 (USD Million)
Figure 31 COPD and asthma therapeutics market: Technology/Software segment dashboard
Figure 32 COPD and asthma therapeutics market: Technology/Software market share analysis, 2024 & 2030
Figure 33 Smart Inhalers with Bluetooth Connectivity market, 2018-2030 (USD Million)
Figure 34 AI-based Respiratory Monitoring Platforms market, 2018-2030 (USD Million)
Figure 35 Mobile Apps for Symptom Tracking market, 2018-2030 (USD Million)
Figure 36 Digital Adherence and Reminder Systems market, 2018-2030 (USD Million)
Figure 37 Telepulmonology Solutions and Reminder Systems market, 2018-2030 (USD Million)
Figure 38 COPD and asthma therapeutics market: Indication market share analysis, 2024 & 2030
Figure 39 Asthma market, 2018-2030 (USD Million)
Figure 40 COPD market, 2018-2030 (USD Million
Figure 41 COPD and asthma therapeutics market revenue, by region
Figure 42 Regional marketplace: Key takeaways
Figure 43 North America COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 44 Key country dynamics
Figure 45 US COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 46 Key country dynamics
Figure 47 Canada COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 48 Key country dynamics
Figure 49 Mexico COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 50 Europe COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 51 Key country dynamics
Figure 52 UK COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 53 Key country dynamics
Figure 54 Germany COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 55 Key country dynamics
Figure 56 France COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 57 Key country dynamics
Figure 58 Italy COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 59 Key country dynamics
Figure 60 Spain COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 61 Key country dynamics
Figure 62 Norway COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 63 Key country dynamics
Figure 64 Sweden COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 65 Key country dynamics
Figure 66 Denmark COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 67 Asia Pacific COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 68 Key country dynamics
Figure 69 Japan COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 70 Key country dynamics
Figure 71 China COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 72 Key country dynamics
Figure 73 India COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 74 Key country dynamics
Figure 75 Australia COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 76 Key country dynamics
Figure 77 South Korea COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 78 Key country dynamics
Figure 79 Thailand COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 80 Latin America COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 81 Key country dynamics
Figure 82 Brazil COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 83 Key country dynamics
Figure 84 Argentina COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 85 MEA COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 86 Key country dynamics
Figure 87 South Africa COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 88 Key country dynamics
Figure 89 Saudi Arabia COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 90 Key country dynamics
Figure 91 UAE COPD and asthma therapeutics market, 2018-2030 (USD Million)
Figure 92 Key country dynamics
Figure 93 Kuwait healthcare information system market, 2018-2030 (USD Million)
Figure 94 Company categorization
Figure 95 Company market position analysis
Figure 96 Strategic framework

Companies Mentioned

The major companies featured in this COPD and Asthma Therapeutics market report include:
  • Teva Pharmaceutical Industries Ltd.
  • GSK plc
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche Ltd
  • AstraZeneca
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Koninklijke Philips N.V.
  • BD
  • Covis Pharma
  • Findair Sp. z o. o.
  • Novartis AG
  • Cipla Ltd.
  • Chiesi Air

Table Information

Report AttributeDetails
No. of Pages120
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 92.3 Billion
Forecasted Market Value ( USD ) by 2030 $ 155.25 Billion
Compound Annual Growth Rate9.1%
Regions CoveredGlobal
No. of Companies Mentioned15

Related Topics

Related Reports

Bronchodilators Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034) - Product Image

Bronchodilators Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • Report
  • 350 Pages
  • Global
From
Asthma Drugs Market Report 2025 - Product Image

Asthma Drugs Market Report 2025

  • Report
  • 250 Pages
  • Global
From
Bronchodilators - Global Strategic Business Report - Product Image

Bronchodilators - Global Strategic Business Report

  • Report
  • 282 Pages
  • Global
From
Bronchodilators Market - Global Forecast 2025-2032 - Product Image

Bronchodilators Market - Global Forecast 2025-2032

  • Report
  • 185 Pages
  • Global
From
Bronchodilator Drug Market - Forecasts from 2025 to 2030 - Product Image

Bronchodilator Drug Market - Forecasts from 2025 to 2030

  • Report
  • 147 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.